Welcome to our dedicated page for Allogene Therapeutics news (Ticker: ALLO), a resource for investors and traders seeking the latest updates and insights on Allogene Therapeutics stock.
Allogene Therapeutics develops allogeneic chimeric antigen receptor T cell, or AlloCAR T, product candidates for cancer and autoimmune disease. The clinical-stage biotechnology company focuses on off-the-shelf CAR T approaches, including cemacabtagene ansegedleucel, or cema-cel, in large B-cell lymphoma and ALLO-329, a dual CD19/CD70 CAR T candidate for autoimmune diseases.
Recurring news covers clinical and regulatory updates for Allogene's studies, scientific presentations and publications, platform technologies such as Dagger®, and data related to MRD-guided treatment approaches. Company updates also include quarterly financial results, business updates, shareholder matters, and common stock financing activity tied to research, development, clinical trials, and corporate operations.
Allogene Therapeutics (ALLO) announced that Executive Vice President and Chief Financial Officer Geoffrey Parker will retire effective November 6, 2026. He will continue to lead the finance organization until his retirement while the company conducts an external search for his successor.
The chief executive officer praised Mr. Parker’s financial leadership and role during a pivotal phase in Allogene’s evolution. Mr. Parker stated he is proud of the company’s accomplishments, remains confident in its strategy and pipeline, and plans to support a smooth transition over the coming months.
Allogene Therapeutics (Nasdaq: ALLO) announced it will participate in the Citi Biopharma Back to School Conference on Wednesday, September 9 at 5:00 a.m. PT / 8:00 a.m. ET. Any available live or replay webcasts will be accessible for about 30 days via the Investors section of the company’s website.
Allogene Therapeutics (Nasdaq: ALLO) reported Q2 2026 results and clinical progress for its allogeneic CAR T pipeline. In the pivotal Phase 2 ALPHA3 trial in first-line LBCL, interim futility analysis showed 58.3% (7/12) MRD negativity with cema-cel versus 16.7% (2/12) with observation, with no treatment-related serious adverse events, CRS, ICANS, GvHD or high-grade infections. FDA granted RMAT and Fast Track designations following this review. Site activation exceeded the 2026 goal early, with ~100 sites now expected by year-end and enrollment completion targeted for year-end 2027, and an EFS update expected mid-2027.
In autoimmune disease, brisk enrollment continues in the Phase 1 RESOLUTION trial of ALLO-329, with a data update planned in Q4 2026. Q2 2026 collaboration revenue was $4.6 million, R&D expense $30.7 million, G&A $20.8 million, and net loss $42.7 million, or $0.13 per share. Cash, cash equivalents and investments totaled $423.6 million at June 30, 2026, with cash runway projected into 2029. 2026 operating expense is expected to be about $165 million, and GAAP operating expenses about $225 million including approximately $35 million of non-cash stock-based compensation.
Allogene Therapeutics (Nasdaq: ALLO) will report its second quarter 2026 financial results and provide a business update on August 12, 2026, after the market close. The company will host a live audio webcast and conference call at 2:00 p.m. PT / 5:00 p.m. ET.
The listen-only webcast will be accessible via the Investors > News and Events section of www.allogene.com, with a replay available for about 30 days. Investors who wish to ask questions on the call must register via the provided link to receive a personal PIN for access.
Allogene Therapeutics (Nasdaq: ALLO) announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to its investigational allogeneic CAR T therapy cemacabtagene ansegedleucel (cema-cel) as first-line consolidation for adult large B-cell lymphoma (LBCL) patients who remain MRD-positive after initial chemoimmunotherapy.
According to Allogene, the designations are based on an interim futility analysis from the pivotal ALPHA3 trial, where 58.3% (7/12) of cema-cel–treated patients achieved MRD negativity by Day 45 versus 16.7% (2/12) in the observation arm, a 41.6% absolute difference. Cema-cel also showed a 97.7% median decrease in plasma ctDNA, compared with a 26.6% median increase with observation, and was reported to be well-tolerated, with no treatment-related serious adverse events, no CRS, ICANS, GvHD or high-grade infections, and no treatment-related hospitalizations. RMAT and Fast Track status enable more frequent FDA engagement and may support expedited development and review.
Allogene Therapeutics (Nasdaq: ALLO) reported full Phase 1 TRAVERSE data for ALLO-316, an allogeneic CD70-targeting CAR T using Dagger® technology, in advanced or metastatic renal cell carcinoma. Twenty-two heavily pretreated Stage IV patients entered Phase 1b; 20 received a single 80M-cell ALLO-316 dose after standard fludarabine/cyclophosphamide lymphodepletion.
The confirmed overall response rate was 25% (5/20), rising to 31% (5/16) in patients with CD70 tumor proportion score ≥50%. Median duration of response and median overall survival in CD70-high patients were not yet reached; one response exceeded 18 months. In Phase 1b, Grade ≥3 toxicities were mainly hematologic, with no Grade 5 events. Cytokine release syndrome occurred in 68% (all Grade <3), infections in 50% (41% Grade ≥3), and IEC-HS in 36% (9% Grade ≥3/4), managed using a protocol-defined algorithm.
Allogene Therapeutics (Nasdaq: ALLO) announced a planned CEO succession. Founder and current CEO David Chang, M.D., Ph.D. will step down as President and CEO on June 30, 2026 and remain on the Board.
Zachary Roberts, M.D., Ph.D., EVP R&D and Chief Medical Officer, becomes President, CEO, and director effective July 1, 2026, after reshaping clinical strategy and leading programs such as the pivotal ALPHA3 trial in first-line LBCL, which recently cleared a positive interim futility analysis.
Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotech developing allogeneic CAR T therapies for cancer and autoimmune disease, will participate in three upcoming investor conferences.
Events include TD Cowen’s Oncology Innovation Summit on May 26, Jefferies Global Healthcare Conference on June 3, and H.C. Wainwright’s Cell Therapy Virtual Conference on June 9. Any available webcasts and 30-day replays will be posted under the Investors > News and Events section of Allogene’s website.
Allogene Therapeutics (Nasdaq: ALLO) reported Q1 2026 results and pipeline progress. Lead asset cema-cel in the pivotal Phase 2 ALPHA3 LBCL trial showed 58.3% MRD clearance vs 16.7% for observation, with no CRS, ICANS, GvHD, treatment-related SAEs or hospitalizations.
Phase 1 ALLO-329 in autoimmune disease has treated nine patients with early signs of activity and tolerability. Q1 net loss was $42.6M; cash was $266.9M plus $200.4M April offering proceeds, extending cash runway into Q1 2029.
Allogene Therapeutics (Nasdaq: ALLO) will report Q1 2026 financial results and provide a business update on May 13, 2026 after market close. A live audio webcast and conference call are scheduled for 2:00 p.m. PT / 5:00 p.m. ET.
Investors can listen via the company's website under Investors > News and Events. A replay will be available for approximately 30 days. Registered participants who wish to ask questions will receive a personal PIN to access the call.